Abstract
Motivational impairments are increasingly recognized as being critical to functional deficits and decreased quality of life in patients diagnosed with psychiatric disease. Accordingly, much preclinical research has focused on identifying psychological and neurobiological processes which underlie motivation . Inferring motivation from changes in overt behavioural responding in animal models, however, is complicated, and care must be taken to ensure that the observed change is accurately characterized as a change in motivation , and not due to some other, task-related process. This chapter discusses current methods for assessing motivation and related psychological processes in rodents. Using an example from work characterizing the motivational impairments in an animal model of the negative symptoms of schizophrenia, we highlight the importance of careful and rigorous experimental dissection of motivation and the related psychological processes when characterizing motivational deficits in rodent models . We suggest that such work is critical to the successful translation of preclinical findings to therapeutic benefits for patients.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS et al (2000) Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 97:8104–8109
American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders. American Psychiatric Publishing, Arlington, VA, USA
Bailey MR, Jensen G, Taylor K, Mezias C, Williamson C, Silver R, Simpson EH, Balsam PD (2015) A novel strategy for dissecting goal-directed action and arousal components of motivated behavior with a progressive hold-down task. Behav Neurosci 129:269–280
Balleine BW, Dickinson A (1998) The role of incentive learning in instrumental revaluation by specific satiety. Anim Learn Behav 26:46–59
Barch DM (2005) The relationships among cognition, motivation, and emotion in schizophrenia: how much and how little we know. Schizophr Bull 31:875–881
Barch DM, Dowd EC (2010) Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions. Schizophr Bull 36:919–934
Barker JM, Zhang H, Villafane JJ, Wang TL, Torregrossa MM, Taylor JR (2014) Epigenetic and pharmacological regulation of 5HT3 receptors controls compulsive ethanol seeking in mice. Eur J Neurosci 39:999–1008
Berridge KC (2000) Measuring hedonic impact in animals and infants: microstructure of affective taste reactivity patterns. Neurosci Biobehav Rev 24:173–198
Berridge KC, Robinson TE (2003) Parsing reward. Trends Neurosci 26:507–513
Bolles RC, Hayward L, Crandall C (1981) Conditioned taste preferences based on caloric density. J Exp Psychol Anim Behav Process 7:59–69
Burbridge JA, Barch DM (2007) Anhedonia and the experience of emotion in individuals with schizophrenia. J Abnorm Psychol 116:30–42
Carroll CA, O’Donnell BF, Shekhar A, Hetrick WP (2009) Timing dysfunctions in schizophrenia span from millisecond to several-second durations. Brain Cogn 70:181–190
Chen C, Takahashi T, Nakagawa S, Inoue T, Kusumi I (2015) Reinforcement learning in depression: a review of computational research. Neurosci Biobehav Rev 55:247–267
Corbit LH, Balleine BW (2005) Double dissociation of basolateral and central amygdala lesions on the general and outcome-specific forms of pavlovian-instrumental transfer. J Neurosci 25:962–970
Corbit LH, Janak PH, Balleine BW (2007) General and outcome-specific forms of Pavlovian-instrumental transfer: the effect of shifts in motivational state and inactivation of the ventral tegmental area. Eur J Neurosci 26:3141–3149
Corbit LH, Balleine BW (2011) The general and outcome-specific forms of Pavlovian-instrumental transfer are differentially mediated by the nucleus accumbens core and shell. J Neurosci 31:11786–11794
Drew MR, Simpson EH, Kellendonk C, Herzberg WG, Lipatova O, Fairhurst S et al (2007) Transient overexpression of striatal D2 receptors impairs operant motivation and interval timing. J Neurosci 27:7731–7739
Ellgood J, Crawley JN (2015) Behavioral and neuroanatomical phenotypes in mouse models of autism. Neurotherapuetics. doi:10.1007/s13311-015-0360-z
Foussias G, Remington G (2010) Negative symptoms in schizophrenia: avolition and Occam’s razor. Schizophr Bull 36:359–369
Gard DE, Kring AM, Gard MG, Horan WP, Green MF (2007) Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure. Schizophr Res 93:253–260
Glendinning JL, Gresack J, Spector AC (2002) A high-throughput screening procedure for identifying mice with aberrant taste and oromotor function. Chem Senses 27:461–474
Gomez J, Marin-Mendez J, Molero P, Atakan Z, Ortuno F (2015) Time perception networks and cognition in schizophrenia: a review and a proposal. Psychiatry Res 220:737–744
Gorwood P (2008) Neurobiological mechanisms of anhedonia. Dialogues Clin Neurosci 10:291–299
Grill HJ, Norgren R (1978) The taste reactivity test. I. Mimetic responses to gustatory stimuli in neurologically normal rats. Brain Res 143:263–279
Hall DA, Stanis JJ, Marquez-Avila H, Gulley JM (2008) A comparison of amphetamine- and methamphetamine-induced locomotor activity in rats: evidence for qualitative differences in behavior. Psychopharmacology 195:469–478
Hammond LJ (1980) The effect of contingency upon the appetitive conditioning of free-operant behavior. J Exp Anal Behav 34:297–304
Herrnstein RJ (1961) Relative and absolute strength of response as a function of frequency of reinforcement. J Exp Anal Behav 4:267–272
Hodos W (1961) Progressive ratio as a measure of reward strength. Science 134:943–944
Hogarty GE, Flesher S, Ulrich R, Carter M, Greenwald D, Pogue-Geile M et al (2004) Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior. Arch Gen Psychiat 61:866–876
Izquierdo A, Belcher AM (2012) Rodent models of adaptive decision making. Methods Mol Biol 829:85–101
Kellendonk C, Simpson EH, Polan HJ, Malleret G, Vronskaya S, Winiger V et al (2006) Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 49:603–615
Killeen PR, Posadas-Sanchez D, Johansen EB, Thrailkill EA (2009) Progressive ratio schedules of reinforcement. J Exp Psychol Anim Behav Process 35:35–50
Mayford M, Bach ME, Huang YY, Wang L, Hawkins RD, Kandel ER (1996) Control of memory formation through regulated expression of a camkII transgene. Science 274:1678–1683
Mayorga AJ, Popke EJ, Fogle CM, Paule MG (2000) Similar effects of amphetamine and methylphenidate on the performance of complex operant tasks in rats. Behav Brain Res 109:59–68
McNamara CG, Davidson ES, Schenk S (1993) A comparison of the motor-activating effects of acute and chronic exposure to amphetamine and methylphenidate. Pharmacol Biochem Behav 45:729–732
Medalia A, Choi J (2009) Cognitive remediation in schizophrenia. Neuropsychol Rev 19:353–364
Mehiel R, Bolles RC (1984) Learned flavor preferences based on caloric outcome. Anim Learn Behav 12:421–427
Muscat R, Willner P (1989) Effects of dopamine receptor antagonists on sucrose consumption and preference. Psychopharmacology 99:98–102
Nestler EJ, Hyman SE (2010) Animal models of neuropsychiatric disorders. Nat Neurosci 13:1161–1169
Olausson P, Jentsch JD, Tronson N, Neve RL, Nestler EJ, Taylor JR (2006) DeltaFosB in the nucleus accumbens regulates food-reinforced instrumental behavior and motivation. J Neurosci 26:9196–9204
O’Tuathaigh CMP, Desbonnet L, Waddington JL (2014) Genetically modified mice related to schizophrenia and other psychoses: seeking phenotypic insights into the pathobiology and treatment of negative symptoms. Eur Neuropsychopharmacol 24:800–821
O’Tuathaigh CMP, Moran PM, Waddington JL (2013) Genetic models of schizophrenia and related psychotic disorders: progress and pitfalls across the methodological “minefield”. Cell Tissue Res 354:247–257
O’Tuathaigh CMP, Kirby BP, Moran PM, Waddington JL (2010) Mutant mouse models: Genotype-phenotype relationships to negative symptoms in schizophrenia. Schizophr Bull 36:271–288
Pagonabarraga J, Kulisevsky J, Strafella AP, Krack P (2015) Apathy in Parkinson’s disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol 14:518–531
Pecina S, Berridge KC (2005) Hedonic hot spot in nucleus accumbens shell: where do u-opioids cause increased hedonic impact of sweetness. J Neurosci 25:11777–11786
Pecina S, Cagniard B, Berridge KC, Aldridge JW, Zhuang X (2003) Hyperdopaminergic mutant mice have higher “wanting” but not “liking” for sweet rewards. J Neurosci 23:9395–9402
Pecina S, Berridge KC, Parker LA (1997) Pimozide does not shift palatability: separation of anhedonia from sensorimotor suppression by taste reactivity. Pharmacol Biochem Behav 58:801–811
Ribot T (1897) The psychology of emotions. W. Scott, London, UK
Richardson NR, Roberts DCS (1996) Progressive ratio schedule of drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J Neurosci Methods 66:1–11
Roberts S (1981) Isolation of an internal clock. J Exp Psychol Anim Behav Process 7:242–268
Salamone JD, Steinpreis RE, McCullough LD, Smith P, Grebel D, Mahan K (1991) Haloperidol and nucleus accumbens dopamine depletion suppress lever pressing for food but increase free food consumption in a novel food choice procedure. Psychopharmacology 104:515–521
Salamone JD, Cousins MS, Bucher S (1994) Anhedonia or anergia? Effects of haloperidol and nucleus accumbens dopamine depletion on instrumental response selection in a T-maze cost/benefit procedure. Behav Brain Res 65:221–229
Salamone JD, Correa M, Mingote S, Weber SM (2003) Nucleus accumbens dopamine and the regulation of effort in food-seeking behavior: implications for studies of natural motivation, psychiatry, and drug abuse. J Pharmacol Exp Ther 305:1–8
Salamone JD, Correa M, Farrar A, Mingote SM (2007) Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits. Psychopharmacology 191:461–482
Simpson EH, Kellendonk C, Ward RD, Richards V, Lipatova O, Fairhurst S et al (2011) Pharmacologic rescue of motivational deficit in an animal model of the negative symptoms of schizophrenia. Biol Psychiatry 69:928–935
Strauss GP, Gold JM (2012) A new perspective on anhedonia in schizophrenia. Am J Psychiatry 169:364–373
Trapold MA (1970) Are expectancies based upon different positive reinforcing events discriminably different? Learn Motivation 1:129–140
Velligan DI, Kern RS, Gold JM (2006) Cognitive rehabilitation for schizophrenia and the putative role of motivation and expectancies. Schizophr Bull 32:474–485
Ward R, Kellendonk C, Simpson EH, Lipatova O, Drew MR, Fairhurst S, Kandel ER, Balsam PD (2009) Impaired timing precision produced by striatal D2 receptor overexpression is mediated by cognitive and motivational deficits. Behav Neurosci 123:720–730
Ward RD, Simpson EH, Kandel ER, Balsam PD (2011) Modeling motivational deficits in mouse models of schizophrenia: Behavior analysis as a guide for neuroscience. Behav Processes 87:149–156
Ward RD, Simpson EH, Richards VL, Deo G, Taylor K, Glendinning JL, Kandel ER, Balsam PD (2012) Dissociation of hedonic reaction to reward and incentive motivation in an animal model of the negative symptoms of schizophrenia. Neuropsychopharmacology 37:1699–1707
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Ward, R.D. (2015). Methods for Dissecting Motivation and Related Psychological Processes in Rodents. In: Simpson, E., Balsam, P. (eds) Behavioral Neuroscience of Motivation. Current Topics in Behavioral Neurosciences, vol 27. Springer, Cham. https://doi.org/10.1007/7854_2015_380
Download citation
DOI: https://doi.org/10.1007/7854_2015_380
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-26933-7
Online ISBN: 978-3-319-26935-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)